Tucotuzumab celmoleukin
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | EpCAM |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| KEGG | |
| Chemical and physical data | |
| Formula | C7812H12124N2044O2408S60 |
| Molar mass | 175.1 kg/mol g·mol−1 |
| (verify) | |
Tucotuzumab celmoleukin is an anti-cancer drug. It is a fusion protein of a humanized monoclonal antibody (tucotuzumab) and an interleukin-2 (celmoleukin).[1][2][3]
This drug was developed by EMD Pharmaceuticals.
References
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |